Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 2 SUPPL., 2002, Pages 37-43

  Edelman, Martin J ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Carboplatin; CDK inhibitors; Combination chemotherapy; COX inhibitors; EFGR inhibitors; Eicosanoids; Gemcitabine; Non small cell lung cancer; Sequential therapy; Targeted therapy

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARACHIDIC ACID; BEXAROTENE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; MITOMYCIN; MULTIPLE EICOSANOID PATHWAY MODULATOR; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN KINASE C INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE; ZILEUTON;

ADVANCED CANCER; ALOPECIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STEROID THERAPY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036844815     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00356-2     Document Type: Conference Paper

References (58)

1. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., et al. Combination chemotherapy vs. single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol. 7:1989;1602-1613.
2. Klastersky J., Sculier J.P., Lacroix H., et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 8:1990;1556-1562.
3. Cardenal F., López-Cabrerizo M., Paz Antón A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 17:1999;12.
4. Sandler A., Nemunaitis J., Dehnam C., et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 18:1998;454a. abstract 1792.
5. Carmichael J., Allerheilgen S., Walling J.A. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol. 23:(suppl 10):1996;55-59.
6. Ng E.W., Sandler A.B., Robinson L., Einhorn L.H. A phase II study of carboplatin plus gemcitabine in advanced non-small cell lung cancer. Am J Clin Oncol. 22:1999;550-553.
7. Edelman MJ, Gandara DR, Lau D, Lauder I. Carboplatin (CBDCA)/gemcitabine (GEM) in NSCLC: Interim analysis of a novel 21 day schedule. Chemotherapy of Non-Small Cell Lung Cancer: Ten Years Later. Perugia International Cancer Conference VI. Perugia, Italy, 1998;6:105.
8. Martinez J., Panizo A., Alonso M.A., et al. Gemcitabine plus carboplatin in advanced non-small cell lung cancer: A phase I trial. Proc Am Soc Clin Oncol. 17:1998;494a.
9. Mazzanti P., Lippe P., Battelli N., et al. Gemcitabine-cisplatin vs. gemcitabine-carboplatin in advanced non-small cell lung cancer: A multicenter phase II randomized trial of a 21 day schedule. Proc Am Soc Clin Oncol. 19:2000;2125.
10. Iaffioli R.V., Tortoriello A., Facchini G., et al. Phase I-II study of gemcitabine and carboplatin in stage IIIb/IV non-small cell lung cancer. J Clin Oncol. 17:1999;9121-9126.
11. Jovits S., Brocato N., Balbiani L., et al. First line therapy with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer: A phase II study. Proc Am Soc Clin Oncol. 18:1999;. abstract 1969.
12. Masotti A., Morandini G. Phase II trial of gemcitabine and carboplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 18:1999;. abstract 1992.
13. Gajra A., Medhdi S.A., Kirshner J., Newman N., Graziano S.L. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer. 32:2001;189-196.
14. Edelman M.J., Clark J., Crowley J., Chansky K., Albain K., Gandara D.R. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer: Carboplatin/gemcitabine (Carb/G>T) followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel (C/V>D) (SWOG 9806). Proc Am Soc Clin Oncol. 20:2001;314a. abstract 1254.
15. Zatloukal P., Petruzelka L., Zemanova M., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with non-small cell lung cancer stage IIb and IV: An interim analysis of a randomized trial. Proc Am Soc Clin Oncol. 20:2001;337a.
16. Danson S., Clemons M., Middleton M., et al. A randomized study of gemcitabine with carboplatin vs. mitomycin, vinblastine and cisplatin or mitomycin, ifosfamide and cisplatin as first line chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 20:2001;322a. abstract 1285.
17. Sederholm C. A phase III study in advanced non-small cell lung cancer (NSCLC) comparing gemcitabine with gemcitabine in combination with carboplatin. Data from the ongoing study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol. 20:2001;324a. abstract 1294.
18. Comella P., Frasci G., Panza N., et al. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 18:2000;1451-1457.
19. Le Chevalier T., Brisgand D., Douillard J.Y., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
20. Wozniak A.J., Crowley J.J., Balcerzak S., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A cooperative group study. J Clin Oncol. 10:1992;1066-1073.
21. Edelman M.J., Quam H., Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small cell lung cancer cell lines. Cancer Chemother Pharmacol. 48:2001;141-144.
22. Hainsworth J.D., Burris H.A. III, Erland J.B., et al. Phase I/II trial of paclitaxel by 1-hour infusion carboplatin and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 85:1999;1269-1276.
23. Kelly K., Mikhaeel-Kamel N., Pan Z., et al. A phase I/II trial of paclitaxel, carboplatin and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 6:2000;3474-3479.
24. Ceresoli G.L., Favaretto A., Paccagnella A., et al. Paclitaxel and carboplatin in combination with gemcitabine: A phase I-II trial in non-small cell lung cancer. Lung Cancer. 29:(suppl 1):2000;6. abstract.
25. Hussein A., Birch R., Waller J. Preliminary results of a randomized study comparing paclitaxel and carboplatin with or without gemcitabine in newly diagnosed non small cell lung cancer. Proc Am Soc Clin Oncol. 19:2000;504a. abstract 1973.
26. Bunn P. Triplet chemotherapy with gemcitabine, a platinum and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol. 26:(1 (suppl 4)):1999;25-30.
27. Comella P., Frasci G., Panza N., et al. Cisplatin-gemcitabine vs. cisplatin-gemcitabine-vinorelbine vs. cisplatin-gemcitabine-paclitaxel in advanced non-small cell lung cancer. First stage analysis of a Southern Italy Cooperative Group (SICOG) phase III trial. Lung Cancer. 29:(suppl 1):2000;79. abstract 258.
28. Pectasides D., Aspropotamitis A., Halikia A., et al. Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol. 17:1999;3816-3821.
29. Day R.S. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res. 46:1986;3876-3885.
30. Norton L., Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 61:1977;1307-1317.
31. Perego P., Giarola M., Righetti S.C., et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56:1996;556-562.
32. Gandara D., Vokes E., Green M., et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: Results of a phase II multicenter trial. J Clin Oncol. 18:2000;131-135.
33. Shepherd F., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2000;2095-2103.
34. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
35. Safran H., King T., Choy H., et al. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer. 78:1996;1203-1210.
36. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 344:2001;1031-1042.
37. Steele V.E., Holmes C.A., Hawk E.T., et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prevention. 8:1999;467-483.
38. Reich R., Martin G.R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins. 1:1996;1-17.
39. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl J Med. 342:2000;1946-1952.
40. Khuri F.R., Hong W., Lee J.J., et al. Cyclooxygenase 2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 7:2001;861-867.
41. Wolff K., Saukkonen K., Antilla S., et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:(22):1998;4997-5001.
42. Ochiai M., Oguri T., Isobe T., et al. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res. 90:(12):1999;1338-1343.
43. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:(5):2000;1306-1311.
44. Asktorab H., Larbi D., Tackey R., et al. Cyclooxygenase-2 inhibitor celecoxib alone and in combination with folic acid inhibits proliferation of colon cancer cell lines. Proc Am Assoc Cancer Res. 42:2001;. abstract 3305.
45. Sofia M.J., Floreancig P., Bach N., et al. The discovery of LY293111, a novel, potent and orally active leukotrience B4 receptor antagonist of the binphenylphenol class. Adv Exp Med Biol. 1997;381-386.
46. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apotosis in human prostate cancer cells. Proc Natl Acad Sci USA. 95:1998;13182-13187.
47. Romano M., Catalano A., Nutini M., et al. 5-Lipoxygenase regulates malignant mesothelial cell survival: Involvement of vascular endothelial growth factor. FASEB J. 2001;2326-2336.
48. Mack P.C., Edelman M.J., Gandara D.R., Gumerlock P.H. Association of RB status with activity of combination 7-hydoxystaurosporine (UCN-01) plus cisplatin (CDDP) treatment in non-small cell lung carcinoma (NSCLC) cell lines. Proc Am Assoc Cancer Res. 39:1998;178. abstract 1220.
49. Monks A., Harris E.D., Vaigro Wolff A., et al. UCN-01 enhances in vitro toxicity of clinical agents in human tumor cell lines. Inv New Drugs. 18:2000;95-107.
50. Thomas P., Robinet G., Lena H., et al. A phase I dose escalation study of carbopiatin and gemcitabine for previously untreated stage IV non-small cell lung cancer. GFPC study 97-01. Proc Am Soc Clin Oncol. 19:2000;522a. abstract 2051.
51. Carrato A., Garcia-Gomez J., Alberola V., et al. Carboplatin in combination with gemcitabine in advanced non-small cell lung cancer. Comparison of two consecutive phase II trials utilizing different schedules. Proc Am Soc Clin Oncol. 18:1999;498a. abstr #1922.
52. Maestu I., Torregosa M.D., Llorca C., et al. Carboplatin and gemcitabine in elderly patients with advanced non-small cell lung cancer. Preliminary results. Eur J Cancer. 35:(suppl 4):1999;S261. abstr #1040.
53. Rudd R.M., Gower N.H., James L.E., et al. Phase III randomised comparison of gemcitabine and carboplatin with mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 21:2002;292a. abstract #1164.
54. Grigorescu A.C., Draghici I.N., Nitipur C., et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VBL) in advanced stages III and IV: a phase III randomized trial. Lung Cancer. 37:2002;9-14.
55. Sederholm C. Gemcitabine compared with gemcitabine plus corboplatin in advanced non-small cell lung cancer: a phase III study by the Swedish Lung Cancer Study Group. Proc Am Soc Clin Oncol. 21:2002;291a. abstract 1162.
56. Zatloukal P., Novakava L., Petruzelka, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with stage IIIB and IV non-small cell lung cancer: final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc Am Soc Clin Oncol. 21:2002;307a. abstract #1125.
57. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer patients who failed platinum and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;293a. abstract #1166.
58. Rioux N., Casonguay A. Inhibitors of lipoxygenase: a new class of chemopreventive agents. Carcinogenesis. 19:1998;1393-1400.